Product Information
KEPPRA 100 MG/ML ORAL SOLN is a brand product labeled by UCB, Inc., priced at $1.9189 per ML under NDC 50474000148. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Jul 15, 2003. Its Orange Book therapeutic-equivalence code is AA.
The High Outlier badge above means this manufacturer's average price in the levetiracetam market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
100 mg/mL
Manufacturer
UCB, Inc.NDC
50474000148
Classification
Brand
Dosage Form
SOLUTION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LEVETIRACETAMApproval Type
New Drug (NDA)
FDA Application
NDA021505FDA Approved
7/15/2003
TE Code
AA
On Market Since
10/20/2003
Pharmacological Classes
Price Statistics
The NADAC for KEPPRA 100 MG/ML ORAL SOLN has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 78.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.9189 per ML |
|---|---|
| All-time high | $1.9234 (May 13, 2026) |
| All-time low | $1.0657 (Dec 18, 2013) |
| 52-week high | $1.9234 |
| 52-week low | $1.8746 |
| Median price | $1.4967 |
| Average price | $1.5455 |
| Largest weekly change | +9.9% (Jan 8, 2014) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 98% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
UCB, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
levetiracetam market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of KEPPRA 100 MG/ML ORAL SOLN?
The current National Average Drug Acquisition Cost (NADAC) for KEPPRA 100 MG/ML ORAL SOLN, manufactured by UCB, Inc., is $1.9189 per ML (NDC 50474000148), effective Sep 30, 2026.
How has the price of KEPPRA 100 MG/ML ORAL SOLN changed over time?
Over the history we have for it, the NADAC for KEPPRA 100 MG/ML ORAL SOLN has risen 78.3%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for KEPPRA 100 MG/ML ORAL SOLN?
Since Nov 28, 2013, the NADAC for KEPPRA 100 MG/ML ORAL SOLN has ranged from a low of $1.0657 (Dec 18, 2013) to a high of $1.9234 (May 13, 2026), with a median of $1.4967 per ML.
Are there cheaper alternatives to KEPPRA 100 MG/ML ORAL SOLN?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LEVETIRACETAM 100 MG/ML SOLN, is $0.0301 per ML — about 98% below KEPPRA 100 MG/ML ORAL SOLN.
Who manufactures KEPPRA 100 MG/ML ORAL SOLN?
KEPPRA 100 MG/ML ORAL SOLN (NDC 50474000148) is labeled by UCB, Inc., and CMS classifies it as a brand product.